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Abstract 
 
The impact of lower serum albumin levels on teicoplanin pharmacokinetics has not been 
previously determined. The authors assessed the relationship between total and free 
concentrations of teicoplanin in serum samples obtained from patients receiving 
teicoplanin therapy for gram-positive bacterial infections. In addition, the authors 
determined the contribution of serum albumin concentrations to the unbound fraction of 
teicoplanin. 
One hundred ninety-eight serum samples were obtained from 65 patients undergoing 
routine therapeutic drug monitoring of teicoplanin. Free serum teicoplanin was 
separated by ultrafiltration, and total and free serum concentrations of teicoplanin were 
determined by a fluorescence polarization immunoassay. Regression analysis was then 
performed to build a prediction model for the free serum teicoplanin concentration from 
the total serum teicoplanin concentration and the serum albumin level using the first 
132 samples. The predictive performance of this model was then tested using the next 
66 samples. 
Free serum teicoplanin concentrations (Cf)(μg/mL) were predicted using a simple model 
constructed using total serum teicoplanin (Ct)(μg/mL) and albumin concentrations 
(ALB)(g/dL): Cf = Ct / (1 + 1.78 * ALB). This model could estimate free serum 
teicoplanin concentrations with a small bias and an acceptable error. The measured free 
level of teicoplanin will lie between 0.63 and 1.38 times the predicted concentration in 
95% of cases.  
Serum albumin level plays a major role in the variability of the fraction unbound of 
teicoplanin. This model can reliably estimate free serum teicoplanin concentrations 
more easily than by using direct measurements. 
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Introduction 
 
Recent reports have recommended that therapeutic drug monitoring be used to 
maintain an adequate serum trough levels when teicoplanin is administered to patients 
with severe infections1,2. In Japan, therapeutic drug monitoring is therefore 
recommended to achieve suitable teicoplanin trough total concentrations (>10μg/mL for 
severe infections) for each patient3.  
Methicillin-resistant Staphylococcus aureus (MRSA) is an organism that causes 
hospital infections in many countries4,5. Teicoplanin and vancomycin are effective drugs 
for the treatment of infections caused by gram-positive cocci, including MRSA6. Recently, 
however, strains that show lower susceptibility to vancomycin has been reported, and 
the appropriate usage of glycopeptides is strongly recommended7,8. Of cause, limiting 
the administration of antibiotics to minimize adaptation is an important concern, but 
also optimizing the dosage regimen for individual patients is also needed to achieve 
sufficient serum concentrations9. Recent studies suggest that teicoplanin exhibits 
time-dependent killing10, and serum trough levels are an important factor in the clinical 
outcome11.  
The pharmacokinetics of teicoplanin has been studied and is known to vary under 
differing conditions, including renal impairment12, renal support therapies13, elderly14, 
and neutropenia15. MRSA infections may occur frequently on such immunocompromised 
hosts. In such patients, lower serum albumin concentrations are often observed16,17.  
Teicoplanin is known to bind strongly to serum albumin. From in vitro studies, it is 
clear that protein binding affects bacterial killing with teicoplanin18. Bernareggi et al. 
reported that the binding of teicoplanin to plasma protein is linear up to about 300mg/L 
and the fraction unbound (fu) value is not dose-dependent between 15 and 25 mg/kg 
dose19. The effect of changing serum albumin levels on the fraction unbound of 
teicoplanin, however, was not determined.  
We assessed the relationship between total and free concentrations of teicoplanin in 
serum samples obtained from patients undergoing routine therapeutic drug monitoring. 
We also determined the contribution of serum albumin concentrations on the fraction 
unbound of teicoplanin.  
Materials and Methods 
 
Subjects 
Between October 1998 and May 2002, 198 serum samples were obtained from the 
routine therapeutic drug monitoring of 68 patients receiving teicoplanin therapy to 
treat gram-positive infections at member hospitals of the Fukui Therapeutic Drug 
Monitoring Research Group. The patients included 43 men and 24 women and had a 
median age of 72years. Median serum creatinine and albumin concentrations prior to 
teicoplanin administration were 0.7mg/dL and 3.2g/dL, respectively. 
Ethics Approval 
In University of Fukui hospital, written consents about routine investigations using 
clinically collected data have been obtained from patients. In other hospitals, research 
use of serum samples for this study was approved by an appropriate organization of 
each institute. 
Determination of Serum Total and Unbound Serum Teicoplanin 
Serum samples were stored at –20℃  until analysis. Unbound teicoplanin was 
separated by ultrafiltration using Centrifree® YM-30 devices (Nihon Millipore, Tokyo, 
Japan). Serum teicoplanin concentrations were assayed by a fluorescence polarization 
immunoassay using a INNOFLUOR® Teicoplanin Assay System (Seradyn, Indianapolis, 
IL, U.S.A) with the TDxFLx system (Abbott Laboratories, Chicago, IL, USA). To assay 
the free serum teicoplanin, certain parameters of the TDxFLx system were changed to 
quantify a lower concentration range. 
 
Determination of Serum Albumin Concentrations 
Serum albumin concentrations were measured by colorimetric detection using 
bromocresol purple20 on an automated analyzer (Nipro, Tokyo, Japan). 
  
Model Development and Validation 
We collected data sets that included total serum teicoplanin concentrations (TEICtotal), 
free serum teicoplanin concentrations (TEICfree), and serum albumin concentrations 
(ALB). The fraction unbound (fu) of teicoplanin was calculated as follows: 
fu = TEICfree / TEICtotal  
These data were separated into two groups according to the time period in which the 
samples were gathered. Of the 198 samples, the first 132 samples were used for the 
model development and the final 66 samples were used to validate the model.  
The parameter characterizing the protein binding of teicoplanin (nKa) was estimated 
using the model development data set by least square regression analysis according to 
the equation below, which is derived from the Scatchard equation:  
TEICfree = TEICtotal / (1+nKa * ALB) 
The value of nKa was the product of the number of binding sites on albumin and the 
association constant. 
To validate this model, the predictive ability for TEICfree was tested using the model 
validation data set. TEICtotal, ALB, and the value of nKa were used to calculate fu and 
determine TEICfree. Predicted and measured TEICfree were analyzed by Altman-Bland 
difference-style plot21. A p value less than 0.05 was considered to be significant. Data 
and statistical analysis were performed using Kyplot software (version 3.0. Kyence, 
Tokyo, Japan). 
 
 
Results 
 
Assay Validation 
The accuracy of the TEICfree assay at concentrations of 0.5, 3.0 and 5.0μg/mL was within 
the ranges of 102-107%. The coefficients of variation (CV) relative to the three 
concentrations of the TEICfree assay in the within- and between-run studies were both 
less than 5%. 
For the TEICtotal assay, all CVs in the within- and between-run studies using 
commercially available control samples were less than 9%. 
 
Sample Characteristics 
The patient characteristics are shown in Table 1. The model-development group 
exhibits significant differences from the model validation group; for example, the 
median serum albumin levels were lower in the model validation group than in the 
model development group. There are no differences on patients’ age, body weight, and 
kidney function in the two patient groups. 
 
Serum Albumin Concentration and the Fraction Unbound of Teicoplanin 
The relationship between serum albumin concentration and the fraction unbound of 
teicoplanin is shown in Figure 1. A marked increase in the fraction unbound was 
observed concurrent with a decrease in the serum albumin levels.  
Intra- and Inter- patients variability of the fraction unbound of teicoplanin 
There are large intra-patients variations of the fraction unbound of teicoplanin in some 
patients. The most considerable case, the fraction unbound of teicoplanin was changed 
0.06 to 0.19 in 2 weeks. Inter-patients variability of the fraction unbound of teicoplanin 
was determined by calculating the coefficient variation (CV) of the patient’s mean of the 
fraction unbound of teicoplanin and yielded 28.8%. 
 
Model Development and Validation 
TEICfree as a function of TEICtotal and ALB is illustrated in Figure 2. The value of nKa 
(±standard error) was 1.78(±0.03)(g/dL)–1. Using this model, TEICfree was predicted by 
the model validation data set. The difference plot for predicted and measured values of 
TEICfree is shown in Figure 3. Because a significant relation was observed between the 
difference and the mean (r=0.31, p=0.011), data were analyzed by log transformed. The 
mean difference is –0.029 μg/mL and limits of agreement (95% confidence interval) are 
–0.20 and 0.14 on the log scale, respectively. Taking the antilog of these limits, it means 
that the measured free level of teicoplanin will lie between 0.63 and 1.38 times the 
predicted concentration in 95% of cases.
Discussion 
In an in vitro study, the killing activity of teicoplanin was affected by the presence of 
serum ultrafiltrate18. This supports the hypothesis that the high degree of protein 
binding may be a factor that affects the killing activity of teicoplanin. From a 
pharmacokinetic theory standpoint, it is clear that only free drugs can pass through 
microvessels and the cell membranes to reach pharmacologic targets (i.e. infection sites 
or pathogenic organs). We should consider free drug concentrations to understand 
delivery and bactericidal activities during infectious disease treatment. However, only a 
small number of reports have discussed free teicoplanin concentrations in clinical 
settings with regard to its strong protein binding capability. Recently, the relationship 
between free steady-state trough teicoplanin concentrations and epithelial lining fluid 
concentrations in patients with ventilator-associated pneumonia was reported22. In this 
paper, the authors reported that free steady-state trough teicoplanin concentrations 
were comparable to concentrations of epithelial lining fluid. They also suggested that 
the fraction unbound of teicoplanin was much higher than expected due to lower levels 
of serum albumin. 
Though further study is needed to confirm the impact of free serum concentrations of 
teicoplanin on its pharmacological effects and adverse drug reactions, technical 
difficulties and complexities related to the monitoring of free serum teicoplanin 
concentrations hinder research in this field. In our study, we developed an improved 
FPIA method to measure lower concentrations of teicoplanin. Our method could 
accurately quantify 0.5μg/mL of teicoplanin in serum filtrate samples. We think that 
the routine analysis of free teicoplanin concentrations is not necessary. Thus, these 
methods of determining free teicoplanin concentrations may help develop a better 
understanding of the pharmacokinetic-pharmacodynamic relationships of teicoplanin.  
Our model, presented in Figure 2, could estimate free serum teicoplanin 
concentrations with a small bias and a slightly large but an acceptable error using total 
teicoplanin concentrations and albumin levels. From the analysis represented in figure 
3, the limits of agreement are –0.20 and 0.14 on the log scale. This means that for about 
95% of cases the result of TEICfree prediction will be between 0.63 and 1.38 times the 
measured TEICfree.  
Renal dysfunction sometimes accompanies hypoalbuminemia, and some reports 
have indicated that the accumulation of endogenous ligands affects phenytoin binding 
to a greater extent than serum albumin concentrations23,24. Based on multiple variable 
analyses, serum urea nitrogen and total bilirubin are not variables that influenced 
teicoplanin protein binding (data not shown). Few uremic patients were included in our 
study, so our results only applicable to the patients who have a similar degree of the 
renal function as presented in Table1. 
Figure 4 is a useful nomogram for the prediction of the free serum concentrations of 
teicoplanin, and was created by calculations at various serum levels using the model 
equation presented in Figure 2. To estimate the free serum teicoplanin concentration, 
only the levels of serum albumin and total teicoplanin are required. Significant 
variability is present in the free teicoplanin fraction both within and between patients. 
During antimicrobial chemotherapy, it is very important to achieve sufficient drug 
exposure to pathogenic organisms. The variability observed in our patients, however, 
suggests that the true exposure might be different even if the same total teicoplanin 
concentrations were obtained. In patients with hypoalbuminemia, a variation of 
fraction unbound of teicoplanin should be considered to avoid unnecessary and costly 
over dosing. Considerable effects of decreased serum albumin levels on the fraction 
unbound of teicoplanin were apparent when serum albumin levels were below 3.0g/dL 
(Fig. 1). This indicates that only for patients with hypoalbuminemia might it be 
necessary to measure the fluctuation of the fraction unbound of teicoplanin.  
Here, we present a clear contribution of serum albumin to the fraction unbound of 
teicoplanin, and also provide a simple model that can predict the free concentration of 
teicoplanin based on the total concentration of teicoplanin. 
Acknowledgements 
 
The authors gratefully acknowledge the efforts of our pharmacy staff for excellent 
technical support. 
  
References 
 
1 MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug 
monitoring of glycopeptides. Ther Drug Monit. 1998; 20: 473-477. 
 
2 Ueda Y, Shibata Y, Ogawa F, et al. Clinical efficacy of teicoplanin against MRSA 
infections in emergency and critical care medicine. Nippon Kagaku Ryoho Gakkai 
Zasshi. 2003; 51: 490-496. 
 
3 Targosid○R  Package insert in Japan. 
 
4 Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant 
Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis. 2004; 10: 1627-1634 
 
5 Kobayashi H. National hospital infection surveillance on Methicillin-resistant 
Staphylococcus aureus. J Hosp Infect. 2005; 60: 172-175 
 
6 Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J 
Antimicrobial Chemother. 1996; 37: 209-222. 
 
7 Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in 
Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working 
Group. N Engl J Med. 1999; 340: 493-501. 
 
8 Song JH, Hiramatsu K, Suh JY, et al. Emergence in asian countries of Staphylococcus 
aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2004; 
48: 4926-4928. 
 
9 Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill 
patients: a retrospective study emphasizing the importance of a loading dose. J 
Antimicrobial Chemother. 2003; 51: 971-975. 
 
10 Garraffo R, Dellamonica P, Drugeon HB, et al.  New approach to optimal antibiotic 
dosage regimen by coupling pharmacokinetics and killing curve parameters. Meth Finf 
Exp Clin Pharmacol. 1990; 12: 79-83 
 
11 Harding I, MacGowan AP, White LO, et al. Teicoplanin therapy for Staphylococcus 
aureus septicaemia: relationship between pre-dose serum concentration and outcome. J 
Antimicrob Chemother 2000; 45: 835-41 
 
12 Derbyshire N, Webb DB, Roberts D, et al. Pharmacokinetics of teicoplanin in subjects 
with varying degrees of renal function. J Antimicrob Chemother 1989; 23: 869-876. 
 
13 Hillaire-Buys D, Peyriere H, Lobjoie E, et al. Influence of arterio-venous 
haemofiltration on teicoplanin elimination. Br J Clin Pharmacol. 1995; 40: 95-97. 
 
14 Rosina R, Villa G, Cavenaghi L, et al. Pharmacokinetics of teicoplanin in the elderly. J 
Antimicrob Chemother. 1988; 21: 39-45. 
 
15 Lortholary O, Tod M, Rizzo N, et al. Population pharmacokinetics study of teicoplanin 
in severely neutropenic patients. Antimicrob Agents Chemother. 1996; 40: 1242-1247. 
 
16 Pirlich M, Schütz T, Kemps M, et al. Prevalance of malnutrition in hospitalized 
medical patients: impact of underlying disease. Digestive Dis. 2003; 21: 245-251. 
 
17 Cupisti A, D’Alessandro C, Morelli E, et al. Nutrition status and dietary manipulation 
in predialysis chronic renal failure patients. J Renal Nutr. 2004; 14: 127-133. 
 
18 Bailey EM, Rybak M, and Kaatz GW. Comparative effect of protein binding on the 
killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother.1991; 
35: 1089-92. 
 
19 Bernareggi A, Borgonovi M, del Favero A, Rosina R, Gavanaghi L. teicoplanin binding 
in plasma following administration of increasing intravenous doses to healthy 
volunteers. Eur J Drug Metab Pharmacokinet 1991; Spec. 3: 256-60 
 
20 Pinnell AE, Northam BE. New automated dye-binding method for serum albumin 
determination with bromcresol purple. Clin Chem 1978; 24: 80-6 
 
21Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet 1986; i 307-10. 
 
22 Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining 
fluid concentrations of teicoplanin 12mg/kg per day in patients with 
ventilator-associated pneumonia. Intensive Care Med 2006; 32:775-9 
  
23 Mabuchi H, Nakanishi H. Isolation and characterization of an endogenous 
drug-binding inhibitor present in uremic serum. Nephron 1986; 44: 277-81 
 24 Mabuchi H, Nakahashi H. A major inhibitor of phenytoin binding to serum protein in 
uremia. Nephron 1988; 48: 310-4. 
 
 
 
 
 
 
Figure Legends 
 
Figure 1 The effects of serum albumin levels on the fraction unbound of teicoplanin. 
Symbols represent the measured fraction unbound of teicoplanin for all patients, and 
the line represents the relationship predicted by the model described in figure 2. 
 
Figure 2 Three-dimensional plot showing the relationship between the concentration of free 
serum teicoplanin as a function of the concentration of total serum teicoplanin and serum 
albumin concentrations in the model developing data set. 
Free serum teicoplanin concentrations were fitted by the least squares regression using the 
model presented in this figure, where n is the number of drug binding sites per albumin 
molecule with their association constant (Ka). Cf and Ct mean free and total serum teicoplanin 
concentrations, respectively. ALB represents serum albumin concentrations. The curved 
surface represents the model fit based on linear regression analysis.  
 
 
Figure 3 Difference plot of measured and predicted free serum teicoplanin 
concentrations in the model validation data set after logarithmic transformation. 
The solid line denotes the mean difference and dashed lines denote upper and lower 
limits of agreement. SD means standard deviation 
  
Figure 4 Nomogram to predict the free serum teicoplanin concentration based on the 
total teicoplanin concentration in patients with various serum albumin levels. 
To estimate the free serum teicoplanin concentration, locate the point on the chart 
where the total serum teicoplanin concentration and the serum albumin intersect. Read 
the value of this point on the Y-axis.  
 
